Title: Management of patients with Paget's disease: a consensus document of the Belgian Bone Club
Authors: Devogelaer, J. -P ×
Bergmann, P
Body, J. -J
Boutsen, Y
Goemaere, S
Kaufman, J. -M
Reginster, J. -Y
Rozenberg, S
Boonen, Steven #
Issue Date: Aug-2008
Publisher: Springer london ltd
Series Title: Osteoporosis International vol:19 issue:8 pages:1109-1117
Abstract: Paget's disease of bone (PDB) is a potentially crippling condition. Pain, fracture, spinal stenosis, nerve entrapment, vascular steal syndrome, secondary osteoarthritis, bone deformity, dental problems, deafness, excessive bleeding during orthopaedic surgery, rare sarcomatous degeneration, and hypercalcaemia constitute complications that may impair the quality of life. The therapeutic approach varies from symptomatic (analgesics, anti-inflammatory drugs) to more specific drugs such as increasingly potent bisphosphonates. Studies such as the PRISM study should in the future help to determine the superiority or not of aggressive treatment over symptomatic treatment in the prevention of complications. Various oral and/or intravenous (I.V.) bisphosphonates have been tested and are currently on the market. The most recently available nitrogen-containing bisphosphonate, I.V. zoledronic acid, is the most potent therapy available for the treatment of PDB. Its therapeutic efficacy, its long-term effect on biologic activity and its good tolerance currently supports its use as a first-line therapeutic option in patients suffering from PDB.
ISSN: 0937-941X
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Gerontology and Geriatrics
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science